Lincoln Pharmaceuticals Limited (BOM:531633)

Lincoln Pharmaceuticals Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	229.89	134.14	57.47	50.52	69.34	138.41
Short-Term Investments	2,089	85.77	77.83	116.57	113.82	-
Trading Asset Securities	-	1,737	1,389	913.26	968.06	806.65
Cash & Short-Term Investments	2,319	1,957	1,524	1,080	1,151	945.06
Cash Growth	17.48%	28.38%	41.11%	-6.16%	21.81%	103.47%
Accounts Receivable	1,698	1,664	1,618	1,363	1,159	1,133
Other Receivables	-	1.67	0.64	1.35	3.4	2.06
Receivables	2,121	2,027	1,922	1,604	1,490	1,333
Inventory	808.24	786.77	771.68	700.28	727.42	466.13
Prepaid Expenses	-	18.09	16.25	19.36	3.73	11.37
Other Current Assets	209.21	210.75	143.83	268.29	156.19	331.8
Total Current Assets	5,458	4,999	4,378	3,672	3,528	3,088
Property, Plant & Equipment	1,873	1,860	1,825	1,569	1,476	1,119
Long-Term Investments	0.03	0.03	0.04	0.03	0.03	1.04
Other Intangible Assets	4.72	4.4	3.26	2.95	3.83	3.98
Other Long-Term Assets	126.41	43.07	47.63	33.74	65.15	59.76
Total Assets	8,545	7,970	7,003	5,874	5,344	4,524
Accounts Payable	884.8	849.48	724.4	508.67	716.67	570.66
Accrued Expenses	-	99.75	90.06	82.92	70.14	58.49
Short-Term Debt	0.67	-	10.67	19.97	20.44	-
Current Portion of Long-Term Debt	-	-	-	-	-	3.75
Current Income Taxes Payable	28.14	-	0.71	8.82	42.77	31.59
Other Current Liabilities	245.82	112.93	96.93	101.08	54.85	93.91
Total Current Liabilities	1,159	1,062	922.77	721.45	904.86	758.4
Long-Term Debt	-	-	-	-	-	1.45
Long-Term Unearned Revenue	57.78	53.85	36.25	47.21	45.39	42.92
Pension & Post-Retirement Benefits	5.36	7.34	0.97	1.39	-	-
Long-Term Deferred Tax Liabilities	164.84	130.02	114.56	79.41	64.55	56.91
Total Liabilities	1,387	1,253	1,075	849.46	1,015	859.67
Common Stock	200.3	200.3	200.3	200.3	200.3	200.3
Additional Paid-In Capital	-	646.17	646.17	646.17	646.17	646.17
Retained Earnings	-	5,969	5,182	4,279	3,580	2,916
Comprehensive Income & Other	6,957	-99.15	-100.06	-100.67	-97.7	-99
Total Common Equity	7,158	6,717	5,928	5,025	4,329	3,664
Shareholders' Equity	7,158	6,717	5,928	5,025	4,329	3,664
Total Liabilities & Equity	8,545	7,970	7,003	5,874	5,344	4,524
Total Debt	0.67	-	10.67	19.97	20.44	5.2
Net Cash (Debt)	2,318	1,957	1,514	1,060	1,131	939.86
Net Cash Growth	18.25%	29.28%	42.76%	-6.22%	20.31%	127.17%
Net Cash Per Share	115.75	97.71	75.58	52.94	56.46	46.92
Filing Date Shares Outstanding	20.02	20.03	20.03	20.03	20.03	20
Total Common Shares Outstanding	20.02	20.03	20.03	20.03	20.03	20
Working Capital	4,298	3,937	3,455	2,951	2,624	2,329
Book Value Per Share	357.45	335.34	295.98	250.86	216.12	183.20
Tangible Book Value	7,153	6,712	5,925	5,022	4,325	3,660
Tangible Book Value Per Share	357.22	335.12	295.82	250.72	215.93	183.00
Land	-	200.24	200.24	187.36	186.32	172.57
Buildings	-	626.46	602.21	580.66	478.61	357.92
Machinery	-	1,675	1,548	1,192	1,031	875.31
Construction In Progress	-	44.7	34.83	67.14	160.54	16.86

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.